Publications by authors named "I Lues"

Claim this Profile
C
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
Torsten Hoffmann, Jens-Ulrich Rahfeld, Mathias Schenk, Falk Ponath, Koki Makioka, Inge Lues

Int J Mol Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.
Thore Hettmann, Stephen D Gillies, Martin Kleinschmidt, Anke Piechotta, Koki Makioka, Inge Lues

Sci Rep· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease.
C T Briels, C J Stam, P Scheltens, S Bruins, I Lues

Clin Neurophysiol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Helen Crehan, Bin Liu, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Kevin X Le, Inge Lues

Alzheimers Res Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Inge Lues

Alzheimers Res Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis